Sumitomo Pharma Valuation Multiples

Sumitomo Pharma Overview

About Sumitomo Pharma

Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Founded

1897

HQ

Employees

6.1K

Website

sumitomo-pharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $3B

EBITDA: $804M

EV

$7B

Valuation Multiples

Multiples.vc

Start free trial

Sumitomo Pharma Financials

Sumitomo Pharma reported last 12-month revenue of $3B and EBITDA of $804M.

In the same LTM period, Sumitomo Pharma generated $804M in EBITDA and $637M in net income.

Sumitomo Pharma P&L

In the most recent fiscal year, Sumitomo Pharma reported revenue of $3B and EBITDA of $465M.

Sumitomo Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Sumitomo Pharma Stock Performance

Sumitomo Pharma has current market cap of $6B, and enterprise value of $7B.

Sumitomo Pharma's stock price is $15.15.

Sumitomo Pharma Valuation Multiples

Sumitomo Pharma trades at 2.6x EV/Revenue multiple, and 9.0x EV/EBITDA.

Sumitomo Pharma Financial Valuation Multiples

As of March 21, 2026, Sumitomo Pharma has market cap of $6B and EV of $7B.

Equity research analysts estimate Sumitomo Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sumitomo Pharma has a P/E ratio of 9.4x.

Sumitomo Pharma Margins & Growth Rates

Sumitomo Pharma's revenue in the last 12 month grew by 15%.

Sumitomo Pharma's revenue per employee in the last FY averaged $0.5M.

Sumitomo Pharma's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sumitomo Pharma's rule of X is 66% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Sumitomo Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Sumitomo Pharma M&A Activity

Sumitomo Pharma acquired XXX companies to date.

Last acquisition by Sumitomo Pharma was on XXXXXXXX, XXXXX. Sumitomo Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Sumitomo Pharma Investment Activity

Sumitomo Pharma invested in XXX companies to date.

Sumitomo Pharma made its latest investment on XXXXXXXX, XXXXX. Sumitomo Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).